Claims for Patent: 10,611,833

Summary for Patent: 10,611,833

Title:	Humanized anti-human epidermal growth factor receptor antibody and application thereof
Abstract:	Disclosed herein are humanized anti-Epidermal Growth Factor (EGF) Receptor antibodies which can inhibit the proliferation of cells expressing the EGF receptor. Humanized anti-EGFR antibodies are capable of binding to the surface of cells and killing the EGF receptor overexpression cells. The invention presents the humanized anti-EGFR antibodies which bind to different epitope and inhibit the tumor formation in a different way than Erbitux. Most importantly, once bound to the surface EGFR, these new anti-EGFR antibodies will internalize rather quickly, which made them ideal candidate for antibody drug conjugation and other biotherapy. The invention also features method of humanization which leads to 90% of the amino acid sequences are human sequence, and significantly reduce the risk of human anti-mouse immunogenicity. The present invention also demonstrated that the humanized anti-EGFR antibodies have the affinity to EGFR in the range of 2.3 nM, which is very similar to the mouse anti-EGFR monoclonal antibody LA22.
Inventor(s):	Le Sun
Assignee:	WELSON PHARMACEUTICALS Inc
Application Number:	US15/124,288

Details for Patent 10,611,833

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034	May 18, 2016	10,611,833	2035-03-06
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034	March 08, 2019	10,611,833	2035-03-06

International Patent Family for US Patent 10,611,833

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2015131855
United States of America	2019010227
China	104059148